In a subset analysis of Chinese patients participating in the PIONEER study, a prospective molecular epidemiology study of EGFR gene mutations in Asian patients newly diagnosed with advanced NSCLC of adenocarcinoma histology, 50.2% (95% CI: 46.6–53.8%) of patients were EGFR mutation positive [12]. Here, EGFR is linked to adenocarcinoma.